Research and experimental development on natural sciences and engineering
LYNGSTADAAS BIOMEDICAL CONSULTING AS
Revenue 2024
NOK 794,000
Operating profit
NOK 451,000
Equity
NOK 2.2m
Incorporated
2004
Share capital
NOK 145,000
Key figures · 2025
Current ratio
15.25
Equity ratio
87.9%
Key figures over time · 2025
| Key figures | 2025 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 56.8% | |
| Net margin (%%) | 55.1% | |
| Return on assets (%%) | 18.2% | |
| Likviditet | ||
| Current ratio | 15.25 | |
| Working capital | 494k | |
| Soliditet | ||
| Equity ratio (%%) | 87.9% | |
| Debt-to-equity ratio | 0.14 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.